PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sereflo Ciphaler (Salmeterol / Fluticasone) DPI - Chronic Obstructive Pulmonary Disease (COPD)
PAD Profile : Sereflo Ciphaler (Salmeterol / Fluticasone) DPI - Chronic Obstructive Pulmonary Disease (COPD)
Brand Names Include :
Sereflo Ciphaler
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Wet age-related macular degeneration
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Diabetic retinopathy
- Osteoarthritis
- Constipation
- Hepatic encephalopathy
- Travellers diarrhoea
- Penile rehabilitation
- Erectile dysfunction
- Cytomegalovirus
- Hyperuricaemia and Gout
- Vitreomacular traction
- Central retinal vein occlusion
- Peripheral arterial disease
- Dysphagia
- Diabetic macular oedema
- Diarrhoea
- Haemorrhoids
- Heart failure
- Oedema
- Lipid modification
- Haemophilia
- Cataracts
- Branch retinal vein occlusion
- Low sexual desire in menopausal women
- Hypertension
- Hypertension
- Hypertension
- Bacterial infection
- Inflammatory bowel disease
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Myopic choroidal neovascularisation
- Cystic fibrosis
- Fungal infection
- Duchenne muscular dystrophy
- Cystic fibrosis
- Hepatitis C
- Tuberculosis
- Hepatitis C
- Multiple sclerosis
- Tuberculosis
- Hepatitis C
- Hepatitis C
- Hepatitis C
- Haemophilia
- Cystic fibrosis
- Hepatitis C
- Systemic Lupus Erythematosus
- Hepatitis C
- Inclusion body myositis
- Cytomegalovirus
- Haemophilia
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Hepatitis C
- Haemophilia
- Systemic Lupus Erythematosus
- Haemophilia
- Haemophilia
- Haemophilia
- Haemophilia
- Multiple sclerosis
- Hepatitis B
- Haemophilia
- Short bowel syndrome
- Haemophilia
- Any paediatric use
- von Willebrand deficiency
- Haemophilia
- Haemophilia
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Mental Health disorders
- Mental Health disorders
- Inflammatory bowel disease
- Acne
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Non-acne dermatological indications
- Anticoagulation reversal
- Restless Leg Syndrome
- von Willebrand deficiency
- Immune thrombocytopenia
- Wet age-related macular degeneration
- Bacterial skin and skin structure infections
- Narcolepsy
- Bacterial lung infection (non-cystic fibrosis)
- Lipid modification
- Menopausal disorders
- All
- Raynaud's Phenomenon
- Atopic dermatitis
- Psoriasis
- Clostridioides difficile
- Covid-19
- Covid-19
- Covid-19
- Inflammatory bowel disease
- Growth failure - children
- Inflammatory bowel disease
- Diabetic macular oedema
- Wet age-related macular degeneration
- Diabetic macular oedema
- Migraine (prevention)
- Urinary incontinence
- Immune thrombocytopenia
- Glaucoma / ocular hypertension
- Dry eyes
- Cancer
- Diarrhoea
- Inflammatory bowel disease
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Tuberculosis
- Tuberculosis
- Tuberculosis
- Covid-19
- Inflammatory bowel disease
- Rehydration in short bowel syndrome
- Faecal impaction (adults)
- Faecal impaction (children)
- Minor digestive complaints
- Haemorrhoids
- Haemorrhoids
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nausea and vomiting
- Agitation in mania and psychotic disorders
- Schizophrenia
- Intraoperative mydriasis / prevention of miosis
- Stoma
- Arrhythmias
- Acute coronary syndrome
- Acute coronary syndrome
- Inotropic support
- IV catheter maintenance
- Cardiopulmonary resuscitation
- Hepatitis D
- Hypertension (severe / crisis)
- Heart failure
- Oedema
- Hypotension
- Tissue glue / suture support
- Diagnosis of Brugada syndrome
- Heparin induced thrombocytopenia
- HIV infection
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Smoking cessation
- Endometriosis
- Surgical diagnostic
- Ocular surgery
- Chronic Obstructive Pulmonary Disease (COPD)
- Growth failure - adults
- Growth failure - children
- Oesophagitis (inducing remission)
- Uterine fibroids
- Overactive bladder (adults)
- Retinal Vein Occlusion
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
28 February 2024
Not Set
This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.
This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.
Associated BNF Codes
03. Respiratory System
03.02.00. Corticosteroids (respiratory)